In conclusion, the Vim-PGI<sub>2</sub> axis is identified as a key regulator of CD8<sup>+</sup> T cell immunity in breast cancer, representing a potential therapeutic target and a critical consideration in anticoagulant management during cancer immunotherapy. This evidence concerns the gene CD8A and breast carcinoma.